Browsing Tag
Guardant Health
15 posts
Abbott adds colorectal cancer blood test to Cologuard portfolio after Freenome FDA win
Freenome wins FDA approval for SimpleScreen CRC, triggering a $100 million Abbott payment and setting up a fall U.S. launch.
Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price
Tempus AI to buy Personalis at $16.25 per share in a $1.5B stock-plus-optional-cash deal, with a $46 Tempus floor that gives Personalis the right to walk if breached.
Verana Health and Guardant Health link genomics and real-world data to accelerate precision oncology drug
Verana Health and Guardant Health (GH) combine EHR and genomic data to accelerate oncology drug development. Read the full strategic analysis.
Guardant Health (NASDAQ: GH) surges 27% after blowout quarter: What it means for diagnostics investors
Find out how Guardant Health’s strong Q3 performance triggered a diagnostics rally — and what it means for investors in the early-detection boom.
Why these five U.S. stocks soared over 20% on October 30: Guardant Health to Metsera
Find out how Guardant Health, FormFactor, Viavi Solutions, Globalstar, and Metsera triggered massive market moves on October 30, 2025.
Liquid biopsy breakthrough: FDA okays Guardant360 CDx to match patients to Eli Lilly’s Inluriyo
FDA approves Guardant360 CDx as a companion diagnostic for Inluriyo in ESR1-mutated breast cancer. Discover how liquid biopsy is reshaping oncology care today.
FDA approval of Eli Lilly’s Inluriyo: Can the new oral SERD reshape advanced breast cancer treatment?
FDA clears Eli Lilly’s Inluriyo for ESR1-mutated advanced breast cancer. Explore trial data, stock sentiment, pricing, and future oncology outlook.
The business of AI in oncology: Who’s building the platforms hospitals trust?
Tempus, Guardant, Freenome, and Paige are building the AI oncology platforms hospitals now rely on. Discover the financials and future shaping cancer diagnostics.
Why has ovarian cancer eluded early screening success—and what’s changing now?
Ovarian cancer screening has failed for decades—now new tests like exosome and cfDNA panels are finally changing the story. Find out what’s driving the shift.
Guardant Health launches Hereditary Cancer Test to expand precision oncology offerings
Guardant Health unveils its new hereditary cancer test to detect inherited genetic risks across 12+ cancer types. Learn how this aids precision treatment plans.